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Purpose: To identify the mutation in the fibrillin-1 gene (FBN1) in a Chinese family with ectopia lentis (EL) and to predict
the structural and functional consequences of the mutation.
Methods: Patients and family members were given complete physical, ophthalmic, and cardiovascular examinations.
Genomic DNA was extracted from leukocytes of venous blood of three affected and three unaffected individuals in the
family, and 100 healthy controls. All 65 coding exons and their flanking intronic boundaries of FBN1 were amplified in
the proband by polymerase chain reaction, followed by direct sequencing. The mutation identified in the proband was
screened for in other family members and 100 healthy controls by direct sequencing. Protein conservation analysis was
performed in seven species using an online ClustalW tool. Protein structure was modeled based on the Protein data bank
and mutated in PyMOL 1.1r1 to predict the structural and functional consequences of the mutation.
Results: A heterozygous c.2262A>G change in exon 18 of FBN1 was detected in the proband, which resulted in the
substitution of tyrosine by cysteine at codon 754 (p.Y754C). This mutation was also present in the affected family
members, but absent in other unaffected family members and 100 healthy controls. The mutant residue, located in the
calcium binding epidermal growth factor-like7 domain, was highly conserved among mammalian species. The mutation
could probably affect the disulfide bond formation of the domain and calcium binding of the adjacent domain, which
would induce a critical functional change of the domain itself and neighboring domains.
Conclusions: We indentified a p.Y754C mutation in FBN1, which is the causative mutation for EL in this family. This
missense mutation introduced an additional cysteine residue by substitution of a highly conserved tyrosine residue within
the cbEGF-like7 module.
Ectopia  lentis  (EL;  OMIM  129600)  is  an  inherited
connective  disorder  characterized  by  lens  dislocation
connected with stretched or discontinuous zonular filaments
[1].  It  often  occurs  as  one  of  the  symptoms  of  Marfan
syndrome (MFS; OMIM 154700), an autosomal dominant
disorder  that  is  characterized  by  manifestations  mainly
involving  the  cardiovascular,  skeletal,  and  ocular  systems
[2]. The diagnosis of MFS is made according to the Ghent
nosology [3]. Isolated EL or predominant EL with relatively
mild skeletal features belongs to Marfan-related disorders as
it does not satisfy the Ghent criteria.
Mutations  in  the  gene  of  human  fibrillin-1  (FBN1),
fibrillin-2 (FBN2), transforming growth factor-β receptor-1
(TGFBR-1),  and  transforming  growth  factor-β  receptor-2
(TGFBR-2) cause MFS [4-7]. Isolated or predominant EL is
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mainly caused by mutations in FBN1 on chromosome 15q21.1
[4]. Human FBN1, a 350 kDa modular glycoprotein, is a major
component  of  the  10–12  nm  extra-cellular  matrix  (ECM)
microfibrils [8]. The structure of fibrillin-1 reveals a highly
repetitive protein that contains three repeated modules: 47
epidermal  growth  factor  (EGF)-like  modules  (43  calcium
binding (or cb) EGF-like modules and 4 non-cb EGF-like
modules), seven transforming growth factor-binding (or TB)
protein like modules (8 Cys/TB), and two hybrid modules
[9]. To date, over 600 FBN1 mutations spread over the entire
gene have been registered in the Universal Mutation Database
(UMD)-FBN1  database  for  MFS  and  its  related  diseases
[10].  Missense  mutations  account  for  a  major  proportion
(more  than  60%)  of  the  pathogenic  mutations,  and  the
majority of these mutations are localized in cbEGF domains
(including  those  which  result  in  substitution  of  calcium-
binding  residues  or  cysteine  residues  involved  in  the
formation of disulphide bonds) [11,12].
Presently, no genotype/phenotype correlations have been
identified except for neonatal MFS [13]. Besides, some recent
studies  showed  strong  correlations  between  isolated  or
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504predominant EL and cysteine substitutions, regardless of its
location within the protein [14]. As a result, long-term study
on genotype/phenotype correlations for MFS and its related
diseases is vital, and molecular analysis of FBN1 is becoming
important  for  the  possibility  of  prenatal  diagnosis  and
detecting at-risk individuals at an early stage for awaking of
serious output of the disease.
In the present study, we investigated a two-generation
family affected with EL and found a missense mutation in the
cbEGF-like7  domain  of  FBN1.  The  mutation  found  in
affected individuals was not observed in any of the healthy
ones.  We  predicted  here  the  structural  and  functional
consequences of the mutation and demonstrated the crucial
role for tyrosine at this position in cbEGF-like domains.
METHODS
Subjects: The family history revealed three affected members
with EL. All the patients (II:3, III:2, and III:3) and three non-
carrier members, including a spouse (II:5, III:1, and II:4), of
the family were given complete physical, ophthalmic, and
cardiovascular examinations after obtaining informed consent
(Figure 1). One hundred control subjects without features of
EL or MFS were also recruited. The study was approved by
Harbin  Medical  University  Ethics  Committee  (Harbin,
China).
Genomic DNA preparation: Whole blood from six available
members of the family (II:3, II:4, II:5, III:1, III:2, and III:3)
and one hundred unrelated controls were collected in tubes
containing EDTA as an anticoagulant. Genomic DNA was
extracted  using  the  TIANamp  Blood  DNA  Kit  (Tiangen
Biltech  Co.  Ltd,  Beijing,  China)  according  to  the
manufacturer’s protocol.
Mutation analysis of FBN1: All 65 coding exons and flanking
intronic regions including splice sites of FBN1 were amplified
by polymerase chain reaction (PCR) using a set of primers
listed in Appendix 1. The PCR products were subsequently
purified  with  a  TIANgel  Midi  Purification  Kit  (Tiangen
Biltech Co. Ltd) and sequenced with an ABI 3130XL Genetic
Analyzer (Applied Biosystems, Foster City, CA). Sequencing
results were assembled and analyzed using the Chromas 2.22
software  (Technelysium  Pty.  Ltd.,  QLD,  Australia)  with
reference sequence (NG_008805) on the NCBI website. The
mutation was confirmed by bidirectional sequencing.
Protein structure analysis: Orthologs of FBN1 were identified
with  the  UMD  and  NCBI  websites,  and  sequences  were
aligned  using  an  online  ClustalW  tool.  Schematic  of  the
cbEGF-like domain of human fibrillin-1 was used to assess
the possible impact of the mutation at the secondary structure
level [15]. A homology 3D model of the cbEGF-like7 domain
was created based on the Protein data bank (PDB) template
1EMN  (47%  sequence  identity),  which  demonstrated  the
solution structure of a pair of cbEGF-like domains of human
fibrillin-1 [12]. PyMOL 1.1r1 was used to display the structure
file and to predict the potential consequence of the mutation.
RESULTS
Clinical features: All affected family members (II:3, III:2, and
III:3) showed similar clinical symptoms: bilateral EL (Figure
2) was discovered in the three patients, and none of them
displayed  skeletal  or  cardiovascular  abnormalities.  The
unaffected family members, including a spouse (II:5, III:1,
and II:4), appeared normal.
Mutation analysis: Direct sequencing of FBN1 revealed a
heterozygous  mutation,  c.2262A>G  in  exon  18,  which
resulted in the substitution of tyrosine by cysteine (p.Y754C;
Figure 3A). The mutation identified in the proband was also
found  in  II:3  and  III:3  (Figure  3B,C).  No  mutation  was
detected in the healthy family members (II:5, III:1, and II:4;
Figure 3D-F) or any of the 100 unrelated control subjects
(Figure 3G).
Potential  consequences  of  the  mutation:  This  missense
mutation c.2262A>G resulted in the substitution of tyrosine
by cysteine at codon 754 in the cbEGF-like7 domain. The
tyrosine754 residue, which was present in 18/43 (42%) cbEGF-
like modules in fibrillin-1, was localized in a β-sheet between
Figure 1. The pedigree of the family.
Squares and circles indicate males and
females, respectively, and the darkened
symbols  represent  the  affected
members.  Symbols  with  a  question
mark  in  the  center  indicate  that  the
member is not diagnosed clearly. The
asterisks  indicate  the  subjects
participating in this study. The patient
above the arrow is the proband.
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505obligatory  cysteine  residues  at  the  C5  and  C6  positions.
Protein conservation analysis showed that the tyrosine754 was
highly conserved among seven mammalian species (Figure
3H). Secondary structure analysis of the cbEGF-like7 domain
revealed that the mutant residue was located at the region
between cysteine750 and cysteine763 (Figure 4A). Prediction by
PyMOL 1.1r1 showed a loss of benzene ring due to the Y754C
mutation and an additional disulfide bond formation between
cysteine750 and cysteine754, which simultaneously disrupted
the  conserved  disulfide  bond  between  cysteine750  and
cysteine763. These led to a critical structure change: the β-sheet
between obligatory glycine753 and aspartic765 transformed to a
loop-region. domain change of this nature could probably alter
the volume of the calcium binding pocket of the posterior
cbEGF-like  domain  because  the  distance  between
cysteine754 and the residues that formed β-turn of the pocket
become farther than in the wild type (Figure 4B −4G). In
addition, the protein surface area of the mutant region was
smaller than that of the wild type (Figure 4H,I). In summary,
the conformation and function of the mutant domain were
likely to be strongly altered by the presence of this mutation,
extending to neighboring domains as well.
Figure 2. Slit lamp photographs of the right eye of the affected family members (III:2, II:3, and III:3 from left to right) after the pupils were
dilated, showing ectopia lentis (superonasally).
Figure 3. A FBN1 mutation in exon 18. A-C: A heterozygous A>G transition (indicated by the arrow) resulted in the substitution of tyrosine
by cysteine (Y754C) in the proband, patient II:3 and III:3 respectively. D-F: The corresponding normal sequence in the unaffected family
member II:5, III:1, and spouse II:4, respectively. G: The corresponding normal sequence in a healthy control. H: The sequence alignment of
FBN1 orthologs surrounding mutated site using ClustalW. The tyrosine754 of human FBN1 protein is highly conserved in several species.
These sequences were selected from the NCBI database.
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In this study, we identified a heterozygous FBN1 mutation (c.
2262A>G) in a Northeast Chinese family affected with EL.
This  missense  mutation  introduced  an  additional  cysteine
residue by substitution of a highly conserved tyrosine residue
within the cbEGF-like7 module.
This mutation, p.Y754C, has been previously reported in
three other families: a large family of European and Australian
Aboriginal origin, and two Central Chinese families [16-18].
All three families met the criteria for a diagnosis of MFS and,
interestingly, the overwhelming majority of members from
each  family  had  lens  subluxation,  with  or  without
cardiovascular and skeletal abnormalities. In our study, the
only manifestation in the family was lens subluxation. These
data demonstrate a complete correlation between p.Y754C
mutation and lens subluxation. Nevertheless, more studies
Figure 4. Structure analyses of the missense mutation in the calcium binding (cb) epidermal growth factor (EGF)-like7 domain. A: The
consensus secondary structure of a prototypical cbEGF-like domain. Calcium binding in the NH2-terminal region of the wild-type domain is
mediated by the consensus sequence (D/N) -X- (D/N) (E/Q) Xm (D/N) Xn (Y/F; m and n are variables), and highly conserved amino acids
are identified by their single-letter amino acid code. The letter C in the schematic represents the highly conserved cysteine of cbEGF-like
domain, and the lines between cysteine represent disulfide bridges. The mutation p.Y754C located at the region between the last two cysteines
of the domain, which could probably interfere with the disulfide bond formation between the two cysteines. B: The 3D structure of the wild
cbEGF-like7–8 domains, which are created based on the Protein Data Bank (PDB) template 1EMN (47% sequence identity) by PyMOL 1.1r1.
The blue represents the unaffected tyrosine. C: The potential conformation change of the mutation. The red represents the substitute cysteine,
where the double β-sheet transformed to a loop-region. D and E: The 3D structure of domains in B and C, respectively. The yellow lines
represent disulfide bonds, and the blue represents the unaffected tyrosine. The purple displays the residues within the distance of 4Å with
tyrosine754, and double β-sheet between obligatory glycine753 and aspartic765. The red represents the substitute cysteine, which absents the
benzene ring. The yellow dashed line represents the potential disulfide bond formation between the introduced cysteine754 and cysteine750,
which would probably disrupt the disulfide bond between cysteine750 and cysteine763. The white displays the residues within the distance of
4Å with cysteine754; compared with the purple wild type, β-turn, which forms the calcium binding pocket of cbEGF-like8, is farther in distance
with cysteine754. F and G: A zoom-in change of D and E, respectively. H and I: The surface of the wild and mutant cbEGF-like7–8 domains,
respectively. The colors correspond to that of figure D and E. The surface area of the mutant region is smaller than that of the wild. In summary,
the conformation of the mutant domain is likely to be strongly altered, to include neighboring domain as well.
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507should be done to confirm this conclusion. To date, eight novel
mutations have been published in the UMD database in the
cbEGF-like7  domain,  and  seven  of  them  are  mutations
creating or substituting cysteine residues [19-23]. A striking
result of a recent study involving over a thousand probands
with MFS and FBN1 mutations is the strong correlation found
between  EL  and  the  presence  of  a  mutation  affecting  a
cysteine residue [14], which also confirms earlier conclusions
on a smaller sample [16,24-27]. These findings suggest that
cysteine residues may have a critical function in suspensory
ligaments  of  the  eyes  and  led  to  the  speculation  that  the
pathophysiology of ectopia lentis is related to a disruption of
the  structural  function  of  fibrillin-1  in  the  10–12  nm
extracellular microfibrils in the ciliary zonule [14,27].
It is clear that EGF-like domains play a major role in the
pathogenesis  of  fibrillinopathies  [28].  Each  cbEGF-like
domain of fibrillin-1 contains six highly conserved cysteine
residues  that  form  three  intra-domain  disulphide  bonds
generating an anti-parallel β-pleated sheet conformation and
a consensus sequence for calcium binding in the NH2-terminal
region [12,29]. In the cbEGF-like7 domain, the intra-domain
disulphide  bonds  are  formed  between  cysteine727  and
cysteine739, cysteine734 and cysteine748, and cysteine  750 and
cysteine 763, respectively, according to the UMD database. The
mutation found in our study, located at the region between
cysteine 750 and cysteine 763, introduced an extra cysteine. A
detailed study performed by PyMOl showed that the extra
cysteine could probably disrupt the third conserved disulfide
bond and introduce an additional one, which would break the
β-sheet between obligatory cysteine 750 and aspartic765. It is
evident that three disulfide bonds are required to maintain the
cbEGF-like module-fold. The loss or addition of cysteine
residues would result in module misfolding, which in turn may
have deleterious effects on the global structure of fibrillin-1
and delay intracellular processing and/or secretion from the
cell  that  lead  to  severe  reduction  of  matrix  deposition
[30-32].  Prediction  by  PyMOL  also  indicated  that  such  a
change of the domain could probably influence the packing
interaction of the cbEGF-like7 and cbEGF-like8 domain and
alter the volume of the calcium-binding pocket of the adjacent
cbEGF-like8  domain,  which  may  affect  calcium  binding
affinity of the cbEGF-like8 and expose the loop between the
cysteines at the C3 and C4 positions to proteases. This would
cause  unexpected  endoplasmic  reticulum  retention  of  the
protein, consistent with a protein folding defect, and increase
the susceptibility of fibrillin peptides to proteolysis [15]. In
support of our speculation, a recent study by Vollbrandt et al.
[33] demonstrated that a C750G substitution of FBN1 that
disrupt the cysteine750-cysteine763 disulfide bond of cbEGF-
like7 caused increased proteolytic susceptibility of cbEGF-
like8. On the protein level, the misfolded domain of the mutant
protein  may  be  degraded  by  intracellular  mechanisms  or
retained  within  the  cell,  or  escape  from  quality  control
surveillance in the cell. For the latter, on encountering the
extracellular space, mutant proteins may be rapidly degraded
by  proteases  in  the  surrounding  environment  or  may
subsequently  disrupt  a  specific  protein–protein  interaction
required  for  the  assembly  of  fibrillin-1  or  interactions  of
microfibrils  with  other  cell-matrix  components  [34].  This
theory can also be proved by immunohistochemical staining
of fibrillin in fibroblast cultures of patients from the Australia
family  carrying  the  same  p.Y754C  mutation:  in  normal
fibroblasts,  most  of  the  fibrillin  was  located  in  the
extracellular area, and the fibers were long, smooth, and fine
in appearance; in mutant fibroblasts, most of the fibrillin was
found within the cells, and the limited amount of fibrillin in
the  extracellular  matrix  was  disorganized  and  appeared
clumped rather than fibrous [16].
Collectively, evidences from our study and published
data supported that the p.Y754C mutation was the causative
mutation for EL in this family. Mutations involving cysteine
substitutions in cbEGF-like domains of FBN1 play a critical
role in the pathogenesis of EL. Our study offers the first
predictions on the structural and functional consequences of
this  mutation  in  detail.  The  result  expands  the  genotype-
phenotype  spectrum  of  FBN1  and  helps  the  study  of  the
molecular pathogenesis of EL and Marfan-related disorders.
ACKNOWLEDGMENTS
We thank all the patients and their family, as well as the
healthy volunteers, for their help and cooperation. This study
was  supported  by  the  Key  Program  of  Natural  Science
Foundation  of  Heilongjiang  Province  (ZD201015),  the
Natural  Science  Foundation  of  Heilongjiang  Educational
Committee (12521261), and a grant from the Key Program of
the Science Foundation of the 2nd Affiliated Hospital, Harbin
Medical University (2010).
REFERENCES
1. Dietz  HC,  Pyeritz  RE.  Mutations  in  the  human  gene  for
fibrillin-1  (FBN1)  in  the  Marfan  syndrome  and  related
disorders.  Hum  Mol  Genet  1995;  4:1799-809.  [PMID:
8541880]
2. Robinson PN, Godfrey M. The molecular genetics of Marfan
syndrome  and  related  microfibrillopathies.  J  Med  Genet
2000; 37:9-25. [PMID: 10633129]
3. Loeys  BL,  Dietz  HC,  Braverman  AC,  Callewaert  BL,  De
Backer  J,  Devereux  RB,  Hilhorst-Hofstee  Y,  Jondeau  G,
Faivre  L,  Milewicz  DM,  Pyeritz  RE,  Sponseller  PD,
Wordsworth P, De Paepe AM. The revised Ghent nosology
for the Marfan syndrome. J Med Genet 2010; 47:476-85.
[PMID: 20591885]
4. Dietz HC, Cutting GR, Pyeritz RE, Maslen CL, Sakai LY,
Corson GM, Puffenberger EG, Hamosh A, Nanthakumar EJ,
Curristin  SM,  Stetten  G,  Meyers  DA,  Francomano  CA.
Marfan syndrome caused by a recurrent de novo missense
mutation  in  the  fibrillin  gene.  Nature  1991;  352:337-9.
[PMID: 1852208]
5. Mizuguchi  T,  Collod-Beroud  G,  Akiyama  T,  Abifadel  M,
Harada N, Morisaki T, Allard D, Varret M, Claustres M,
Molecular Vision 2012; 18:504-511 <http://www.molvis.org/molvis/v18/a55> © 2012 Molecular Vision
508Morisaki H, Ihara M, Kinoshita A, Yoshiura K, Junien C,
Kajii  T,  Jondeau  G,  Ohta  T,  Kishino  T,  Furukawa  Y,
Nakamura  Y,  Niikawa  N,  Boileau  C,  Matsumoto  N.
Heterozygous TGFBR2 mutations in Marfan syndrome. Nat
Genet 2004; 36:855-60. [PMID: 15235604]
6. Singh  KK,  Rommel  K,  Mishra  A,  Karck  M,  Haverich  A,
Schmidtke J, Arslan-Kirchner M. TGFBR1 and TGFBR2
mutations in patients with features of Marfan syndrome and
Loeys Dietz syndrome. Hum Mutat 2006; 27:770-7. [PMID:
16799921]
7. Sakai H, Visser R, Ikegawa S, Ito E, Numabe H, Watanabe Y,
Mikami H, Kondoh T, Kitoh H, Sugiyama R, Okamoto N,
Ogata T, Fodde R, Mizuno S, Takamura K, Egashira M,
Sasaki N, Watanabe S, Nishimaki S, Takada F, Nagai T,
Okada Y, Aoka Y, Yasuda K, Iwasa M, Kogaki S, Harada N,
Mizuguchi T, Matsumoto N. Comprehensive genetic analysis
of four relevant genes in 49 patients with Marfan syndrome
or  Marfan-related  phenotypes.  Am  J  Med  Genet  2006;
140:1719-25. [PMID: 16835936]
8. Sakai  LY,  Keene  DR,  Engvall  E.  Fibrillin,  a  new  350-kD
glycoprotein, is a component of extracellular microfibrils. J
Cell Biol 1986; 103:2499-509. [PMID: 3536967]
9. Collod-Béroud G, Boileau C. Marfan syndrome in the third
Millennium.  Eur  J  Hum  Genet  2002;  10:673-81.  [PMID:
12404097]
10. Stheneur C, Collod-Béroud G, Faivre L, Buyck JF, Gouya L,
Le Parc JM, Moura B, Muti C, Grandchamp B, Sultan G,
Claustres M, Aegerter P, Chevallier B, Jondeau G, Boileau C.
Identification of the minimal combination of clinical features
in probands for efficient mutation detection in the FBN1 gene.
Eur J Hum Genet 2009; 17:1121-8. [PMID: 19293843]
11. Collod-Béroud G, Le Bourdelles S, Ades L, Ala-Kokko L,
Booms P, Boxer M, Child A, Comeglio P, De Paepe A,
Hyland  JC,  Holman  K,  Kaitila  I,  Loeys  B,  Matyas  G,
Nuytinck  L,  Peltonen  L,  Rantamaki  T,  Robinson  P,
Steinmann B, Junien C, Béroud C, Boileau C. Update of the
UMD-FBN1  mutation  database  and  creation  of  an  FBN1
polymorphism  database.  Hum  Mutat  2003;  22:199-208.
[PMID: 12938084]
12. Downing AK, Knott V, Werner JM, Cardy CM, Campbell ID,
Handford PA. Solution structure of a pair of calcium-binding
epidermal growth factor-like domains: implications for the
Marfan syndrome and other genetic disorders. Cell 1996;
85:597-605. [PMID: 8653794]
13. Tiecke  F,  Katzke  S,  Booms  P,  Robinson  PN,  Neumann  L,
Godfrey M, Mathews KR, Scheuner M, Hinkel GK, Brenner
RE, Hovels-Gurich HH, Hagemeier C, Fuchs J, Skovby F,
Rosenberg T. Classic, atypically severe and neonatal Marfan
syndrome:  twelve  mutations  and  genotype-phenotype
correlations in FBN1 exons 24–40. Eur J Hum Genet 2001;
9:13-21. [PMID: 11175294]
14. Faivre L, Collod-Beroud G, Loeys BL, Child A, Binquet C,
Gautier  E,  Callewaert  B,  Arbustini  E,  Mayer  K,  Arslan-
Kirchner M, Kiotsekoglou A, Comeglio P, Marziliano N,
Dietz HC, Halliday D, Beroud C, Bonithon-Kopp C, Claustres
M, Muti C, Plauchu H, Robinson PN, Adès LC, Biggin A,
Benetts B, Brett M, Holman KJ, De Backer J, Coucke P,
Francke U, De Paepe A, Jondeau G, Boileau C. Effect of
mutation  type  and  location  on  clinical  outcome  in  1,013
probands with Marfan syndrome or related phenotypes and
FBN1 mutations: an international study. Am J Hum Genet
2007; 81:454-66. [PMID: 17701892]
15. Whiteman  P,  Willis  AC,  Warner  A,  Brown  J,  Redfield  C,
Handford  PA.  Cellular  and  molecular  studies  of  Marfan
syndrome mutations identify co-operative protein folding in
the cbEGF12–13 region of fibrillin-1. Hum Mol Genet 2007;
16:907-18. [PMID: 17324963]
16. Summers KM, Xu D, West JA, McGill JJ, Galbraith A, Whight
CM, Brocque SL, Nataatmadja M, Kong LK, Dondey J, Stark
D,  West  MJ.  An  integrated  approach  to  management  of
Marfan syndrome caused by an FBN1 exon 18 mutation in an
Australian  Aboriginal  family.  Clin  Genet  2004;  65:66-9.
[PMID: 15032979]
17. Xu D, Wan F, Wang J. A novel mutation in exon 18 of the FBN1
gene causes Marfan syndrome with cardiovascular and ocular
abnormatities. Beijing Medical Journal 2001; 23:34-6.
18. Hao P, Tang X, Song H, Wang L, Wang Y, Ying M, Han R, Li
N. Screening of FBNl gene mutations in a family with Marfan
syndrome. Zhonghua Yan Ke Za Zhi 2010; 46:984-8. [PMID:
21211293]
19. Katzke S, Booms P, Tiecke F, Palz M, Pletschacher A, Turkmen
S, Neumann LM, Pregla R, Leitner C, Schramm C, Lorenz P,
Hagemeier C, Fuchs J, Skovby F, Rosenberg T, Robinson PN.
TGGE screening of the entire FBN1 coding sequence in 126
individuals  with  Marfan  syndrome  and  related
fibrillinopathies.  Hum  Mutat  2002;  20:197-208.  [PMID:
12203992]
20. Nijbroek G, Sood S, McIntosh I, Francomano CA, Bull E,
Pereira L, Ramirez F, Pyeritz RE, Dietz HC. Fifteen novel
FBN1  mutations  causing  Marfan  syndrome  detected  by
heteroduplex  analysis  of  genomic  amplicons.  Am  J  Hum
Genet 1995; 57:8-21. [PMID: 7611299]
21. Halliday  DJ,  Hutchinson  S,  Lonie  L,  Hurst  JA,  Firth  H,
Handford PA, Wordsworth P. Twelve novel FBN1 mutations
in Marfan syndrome and Marfan related phenotypes test the
feasibility of FBN1 mutation testing in clinical practice. J
Med Genet 2002; 39:589-93. [PMID: 12161601]
22. Hayward C, Rae AL, Porteous ME, Logie LJ, Brock DJ. Two
novel mutations and a neutral polymorphism in EGF-like
domains of the fibrillin gene (FBN1): SSCP screening of
exons 15–21 in Marfan syndrome patients. Hum Mol Genet
1994; 3:373-5. [PMID: 8004112]
23. Oh MR, Kim JS, Beck NS, Yoo HW, Lee HJ, Kohsaka T, Jin
DK. Six novel mutations of the fibrillin-1 gene in Korean
patients  with  Marfan  syndrome.  Pediatr  Int  2000;
42:488-91. [PMID: 11059536]
24. Loeys B, De Backer J, Van Acker P, Wettinck K, Pals G,
Nuytinck  L,  Coucke  P,  De  Paepe  A.  Comprehensive
molecular  screening  of  the  FBN1  gene  favors  locus
homogeneity  of  classical  Marfan  syndrome.  Hum  Mutat
2004; 24:140-6. [PMID: 15241795]
25. Biggin A, Holman K, Brett M, Bennetts B, Adès L. Detection
of  thirty  novel  FBN1  mutations  in  patients  with  Marfan
syndrome  or  a  related  fibrillinopathy.  Hum  Mutat  2004;
23:99. [PMID: 14695540]
26. Arbustini E, Grasso M, Ansaldi S, Malattia C, Pilotto A, Porcu
E,  Disabella  E,  Marziliano  N,  Pisani  A,  Lanzarini  L,
Mannarino S, Larizza D, Mosconi M, Antoniazzi E, Zoia MC,
Meloni G, Magrassi L, Brega A, Bedeschi MF, Torrente I,
Mari  F,  Tavazzi  L.  Identification  of  sixty-two  novel  and
Molecular Vision 2012; 18:504-511 <http://www.molvis.org/molvis/v18/a55> © 2012 Molecular Vision
509twelve  known  FBN1  mutations  in  eighty-one  unrelated
probands with Marfan syndrome and other fibrillinopathies.
Hum Mutat 2005; 26:494. [PMID: 16222657]
27. Rommel  K,  Karck  M,  Haverich  A,  von  Kodolitsch  Y,
Rybczynski M, Muller G, Singh KK, Schmidtke J, Arslan-
Kirchner M. Identification of 29 novel and nine recurrent
fibrillin-1  (FBN1)  mutations  and  genotype-phenotype
correlations in 76 patients with Marfan syndrome. Hum Mutat
2005; 26:529-39. [PMID: 16220557]
28. Schrijver I, Liu W, Brenn T, Furthmayr H, Francke U. Cysteine
substitutions  in  epidermal  growth  factor-like  domains  of
fibrillin-1:  distinct  effects  on  biochemical  and  clinical
phenotypes. Am J Hum Genet 1999; 65:1007-20. [PMID:
10486319]
29. Reinhardt DP, Ono RN, Sakai LY. Calcium stabilizes fibrillin-1
against  proteolytic  degradation.  J  Biol  Chem  1997;
272:1231-6. [PMID: 8995426]
30. Jin C, Yao K, Jiang J, Tang X, Shentu X, Wu R. Novel FBN1
mutations  associated  with  predominant  ectopia  lentis  and
marfanoid  habitus  in  Chinese  patients.  Mol  Vis  2007;
13:1280-4. [PMID: 17679947]
31. Robinson PN, Booms P. The molecular pathogenesis of the
Marfan syndrome. Cell Mol Life Sci 2001; 58:1698-707.
[PMID: 11706995]
32. Schrijver I, Liu W, Brenn T, Furthmayr H, Francke U. Cysteine
substitutions  in  epidermal  growth  factor-like  domains  of
fibrillin-1:  distinct  effects  on  biochemical  and  clinical
phenotypes. Am J Hum Genet 1999; 65:1007-20. [PMID:
10486319]
33. Vollbrandt T, Tiedemann K, El-Hallous E, Lin G, Brinckmann
J, John H, Bätge B, Notbohm H, Reinhardt DP. Consequences
of cysteine mutations in calcium-binding epidermal growth
factor  modules  of  fibrillin-1.  J  Biol  Chem  2004;
279:32924-31. [PMID: 15161917]
34. Suk JY, Jensen S, McGettrick A, Willis AC, Whiteman P,
Redfield  C,  Handford  PA.  Structural  consequences  of
cysteine  substitutions  C1977Y  and  C1977R  in  calcium-
binding epidermal growth factor-like domain 30 of human
fibrillin-1.  J  Biol  Chem  2004;  279:51258-65.  [PMID:
15371449]
Molecular Vision 2012; 18:504-511 <http://www.molvis.org/molvis/v18/a55> © 2012 Molecular Vision
510Appendix 1. Primers used for FBN1 amplification.
Summary of the primers used for the amplification of
FBN1 exons. Sequences are given in the 5'→3' direction. To
access the data, click or select the words “Appendix 1.” This
will initiate the download of a compressed (pdf) archive that
contains the file.
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